Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?

被引：2
|
作者：
Lahaye, Clement [1 ,2 ]
Soubrier, Martin [3 ]
机构：
[1] Ctr Hosp talier niv Clermont Ferrand, Serv Geriatrie, Clermont Ferrand, France
[2] Univ Clermont Auvergne, Inst Natl Rech Agr Alimentat & Environm, Unite Nutr Humaine, Ctr Rech Nutr Humaine Auvergne, Clermont Ferrand, France
[3] Ctr Hosp Univ Clermont Ferrand, Serv Rhumatol, Clermont Ferrand, France
来源：
NATURE REVIEWS RHEUMATOLOGY | 2020年 / 16卷 / 07期
关键词：
FRAILTY;
D O I：
10.1038/s41584-020-0411-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Methotrexate is commonly used in combination with biologic DMARDs in the treatment of rheumatoid arthritis on the basis that the combined therapy has synergistic benefits. New data challenge this concept in the treatment of older adults and highlight the uncertainty of the mode of action of methotrexate in this population.
引用
收藏
页码：353 / 354
页数：2
相关论文
共 50 条
  • [1] Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?
    Clément Lahaye
    Martin Soubrier
    Nature Reviews Rheumatology, 2020, 16 : 353 - 354
  • [2] Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
    Bechman, Katie
    Oke, Anuoluwapo
    Yates, Mark
    Norton, Sam
    Dennison, Elaine
    Cope, Andrew P.
    Galloway, James B.
    RHEUMATOLOGY, 2020, 59 (09) : 2563 - 2571
  • [3] Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers
    Arora, Anamika
    Mahajan, Anadi
    Spurden, Dean
    Boyd, Helen
    Porter, Duncan
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2013, 2013
  • [4] Does Aggressive Intervention in Elderly Patients With STEMI Improve Survival?
    Shaw, Peter
    Joffe, Samuel W.
    Akhter, Mohammed
    Lessard, Darleen
    Yarzebski, Jorge
    Gore, Joel
    Goldberg, Robert J.
    CIRCULATION, 2013, 128 (22)
  • [5] Drug survival time on anti-TNF agents: Does prior anti-TNF use influence RA outcomes?
    Kishimoto, M
    Greenberg, J
    Abramson, SB
    Harrington, T
    Olenginski, TP
    Kafka, SP
    Reed, G
    Hinkle, K
    Kremer, J
    Cohen, SB
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S347 - S347
  • [6] Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?
    Nocturne, Gaetane
    Seror, Raphaele
    Mariette, Xavier
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02)
  • [7] Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register (vol 59, pg 2563, 2020)
    Bechman, Katie
    Oke, Anuoluwapo
    Yates, Mark
    Norton, Sam
    Dennison, Elaine
    Cope, Andrew P.
    Galloway, James B.
    RHEUMATOLOGY, 2021, 60 (04) : 2033 - 2033
  • [8] Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
    Kwon, Oh Chan
    Park, Jung Hwan
    Park, Min-Chan
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [9] Response and Drug Survival of 1st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis - What Is the Role of Co-Medication with Methotrexate?
    Fagerli, Karen M.
    Lie, Elisabeth
    van der Heijde, Desiree
    Heiberg, Marte S.
    Rodevand, Erik
    Lexberg, Ase S.
    Kalstad, Synnove
    Mikkelsen, Knut
    Kvien, Tore K.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1082 - S1082
  • [10] DOES IMMUNOGENICITY INFLUENCE ON DRUG SURVIVAL OF ANTI-TNF?
    Garcia-Carazo, S.
    Plasencia, C.
    Pascual-Salcedo, D.
    Lopez-Casla, M.
    Moral, R.
    Nuno, L.
    Bonilla Hernan, G.
    Villalba, A.
    Peiteado, D.
    Diaz, M.
    Martin-Mola, E.
    Balsa, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 481 - 481
12345